Desire Me

Desire Me | PT-141

Explore personalized care for concerns about low sexual desire with Desire Me, featuring PT-141, also known as bremelanotide. A medical evaluation helps determine the possible causes of your concerns and whether treatment is appropriate.

PT-141 | Bremelanotide
PT-141 is a synthetic peptide that activates melanocortin receptors involved in sexual-response pathways. Bremelanotide’s FDA-approved formulation, Vyleesi, treats acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women.

Eligibility depends on your symptoms, health history, and medications. It is not indicated to enhance sexual performance, and compounded PT-141 should not be represented as an FDA-approved product.

Results vary. A consultation with our medical provider is required to determine eligibility and recommend an appropriate treatment plan.